

**ImmunID announces the appointment of Alain Fléché as Board member.
Alain Fléché, former vice president at Roche Diagnostics France joins the board of ImmunID**

Grenoble, France, July 1st 2010 – ImmunID, specializing in innovative diagnostics in immunomonitoring and personalized medicine in the fields of cancer and infectious diseases, announced today the appointment of Alain Fléché as a new member of its Board.

"We are delighted that Alain Fléché has accepted our invitation to join the board of ImmunID. Through his extensive expertise in the field of molecular biology diagnostics and his experience of the regulatory aspects of our profession, he will be a great asset to the team" indicates Nicolas Pasqual CEO at ImmunID. *"Mr. Fléché will bring his experience to bear in helping with our market launch strategy for our innovative tests, he will also add to our knowledge of the diagnostics industry at the highest international level."*

"ImmunID is a biotechnology company fully focused on the development of highly innovative tools which allow health professionals to better understand the immune response of each individual patient, and thus to adapt their treatment, in particular in the field of cancer." declares Alain Fléché. *"I am proud to be able to offer my experience of the in vitro diagnostics market to a dynamic team who develops original biomarkers in the promising field of personalized medicine"*

"The arrival of Alain Fléché in the board of ImmunID is very important to us: it means that, like us, he has seen what ImmunID has to offer and has recognized its worth. In addition, his experience and personality will be a great asset to the Board" indicates Karine Lignel of Vizille Capital Innovation and Sudinnova.

"We are very pleased that Alain Fléché will join the Board of ImmunID. He has extensive experience of the in vitro diagnostics sector and in particular of market launches for innovative products" continues Célia Hart of CEA investment.

About Alain Fléché: Alain Fléché holds a biochemical engineering degree from INSA Lyon, his career so far has been entirely pursued within the Swiss pharmaceutical group Roche, in particular in the diagnostics branch which has a vocation to design, create and sell products used in medical analysis laboratories, research laboratories in the Health sector, and by patients themselves. Following a period as head of Sales and Marketing when he completed his management training at CPA Paris, he was appointed Vice President of Roche Diagnostics whose French headquarters are located in Meylan (Isère). In this position he was particularly involved in managing strategic global projects. For over 14 years he simultaneously occupied different roles within the *in vitro* diagnostics industry's union (SFRL) which groups together all the active companies involved in the diagnostics sector in France. From 2002 to 2008 he was President of this Union and through his communications to the large Institutions he was instrumental in highlighting the key position of biological diagnosis in the care pathway.

About ImmunID: Located in Grenoble and Lyon, ImmunID is leader in the field of analysis of the combinatorial diversity of the immune repertoire. Thanks to the original concept of "immune forecast" ImmunID offers diagnostic and innovative immunomonitoring solutions to characterize dysfunctions of the immune system or to analyze the impact of immune-targeted therapies on the immune repertoire. In the Biotech & Pharma sector, the ImmunTraCkeR® and Immun'Ig® solutions are used from the discovery stage through to clinical validation to measure the security and efficacy of molecules such as monoclonal antibodies (e.g. anti-CD20), interleukins (IL-2, IL-7 etc.), vaccines (prophylactic and therapeutic).